TALLAHASSEE, Fla. – Trulieve Cannabis Corp (CSE: TRUL) (OTC: TCNNF) (“Trulieve” or the “Company”), a leading and top-performing cannabis company in the United States, today announces the launch of a new product to further extend its variety of quality cannabis offerings for Florida patients. TruKief will provide patients with an attractive addition to TruFlower in rotating strains of Sativa, Indica, and Hybrid.
TruKief is a raw cannabinoid medicine derived from flower. It is a cost-effective solution that is administered through inhalation and delivers a higher percentage of cannabinoids than flower. TruKief is isolated mechanically, with controlled temperature, from our flower processing lines. This high potency flower product has less plant material, reducing risk of potential irritation.
“Trulieve is thrilled to offer TruKief to our community and meet the growing demand for a high THC product,” said Valda Coryat, chief marketing officer at Trulieve. “For patients focused on minimizing the cost of their relief, looking for experimental flexibility, or those that desire solvent-less concentrates, Trulieve continues to be the leading source for both quality and accessibility with our new TruKeif option.”
TruKief will be available starting July 7th in Trulieve’s dispensaries, and via online ordering for delivery or pick up in-store or curbside.
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF. To learn more about Trulieve, visit www.Trulieve.com